Page last updated: 2024-08-21

hydrazine and Thyroid Cancer, Anaplastic

hydrazine has been researched along with Thyroid Cancer, Anaplastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baloglu, E; Ding, LW; Doan, NB; Ganesan, TS; Garg, M; Kanojia, D; Kauffman, M; Koeffler, HP; Mayakonda, A; Nagare, RP; S, S; Sadhanandhan, B; Said, JW; Shacham, S; Suresh, S	1

Other Studies

1 other study(ies) available for hydrazine and Thyroid Cancer, Anaplastic

Article	Year
Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Scientific reports, 2017, 08-29, Volume: 7, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Disease Models, Animal; Doxorubicin; Exportin 1 Protein; Heterografts; Humans; Hydrazines; Karyopherins; Models, Biological; Neoplasm Transplantation; Receptors, Cytoplasmic and Nuclear; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Triazoles; Tumor Cells, Cultured	2017

Article

Year

Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.

Scientific reports, 2017, 08-29, Volume: 7, Issue:1

Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Disease Models, Animal; Doxorubicin; Exportin 1 Protein; Heterografts; Humans; Hydrazines; Karyopherins; Models, Biological; Neoplasm Transplantation; Receptors, Cytoplasmic and Nuclear; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Triazoles; Tumor Cells, Cultured

2017